Roughly a month after announcing plans to merge several units under Sumitomo Pharma America this July, the drugmaker is making cuts in Massachusetts.
Sumitomo Pharma America Holdings and Sumitomo Pharma Oncology have announced a combined 122 layoffs to take effect June 30, according to Massachusetts’ WARN system. Another Sumitomo unit, Sunovion Pharmaceuticals, will make 101 cuts.
Sumitomo announced in early April that it was combining Sunovion, Sumitomo Pharma Oncology, Sumitomo Pharma America Holdings, Sumitovant Biopharma, Myovant Sciences, Urovant Sciences and Enzyvant Therapeutics to form Sumitomo Pharma America. Sumitomo said at the time that the combined company would house a “diverse portfolio of commercialized products and robust pipeline of early- to late-stage assets” across the central nervous system, oncology, urology, women’s health, and cell and gene therapies.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 167,200+ biopharma pros reading Endpoints daily — and it’s free.